CD8 T cells compensate for impaired humoral immunity in COVID-19 patients with hematologic cancer.
Bange EM, Han NA, Wileyto P, Kim JY, Gouma S, Robinson J, Greenplate AR, Porterfield F, Owoyemi O, Naik K, Zheng C, Galantino M, Weisman AR, Ittner CAG, Kugler EM, Baxter AE, Oniyide O, Agyekum RS, Dunn TG, Jones TK, Giannini HM, Weirick ME, McAllister CM, Babady NE, Kumar A, Widman AJ, DeWolf S, Boutemine SR, Roberts C, Budzik KR, Tollett S, Wright C, Perloff T, Sun L, Mathew D, Giles JR, Oldridge DA, Wu JE, Alanio C, Adamski S, Garfall AL, Vella L, Kerr SJ, Cohen JV, Oyer RA, Massa R, Maillard IP; UPenn COVID Processing Unit; Maxwell KN, Reilly JP, Maslak PG, Vonderheide RH, Wolchok JD, Hensley SE, Wherry EJ, Meyer N, DeMichele AM, Vardhana SA, Mamtani R, Huang AC.
Bange EM, et al. Among authors: mathew d.
Res Sq [Preprint]. 2021 Feb 2:rs.3.rs-162289. doi: 10.21203/rs.3.rs-162289/v1.
Res Sq. 2021.
PMID: 33564756
Free PMC article.
Updated.
Preprint.